Verubecestat linked to worse outcomes among patients with prodromal Alzheimer’s Disease compared to placebo
1. Verubecestat, an orally administered beta amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor , did not slow or prevent the progression ...